Europe Anemia Drugs Market Analysis

Europe Anemia Drugs Market Analysis

$ 3999

Europe's Anemia drugs market was valued at $3.04 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.64% from 2022 to 2030 and will reach $5.47 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Amgen, AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & Johnson, Pfizer, and Sanofi among others.

ID: IN10EUPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Europe AUTHOR: Nandini Shah

Buy Now

Europe Anemia Drugs Market Executive Summary

The Europe Anemia Drugs market was valued at $3.04 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.64% from 2022 to 2030 and will reach $5.47 Bn in 2030. Anemia is a disorder that causes fatigue, weakness, and other symptoms due to a lack of red blood cells or hemoglobin. Anemia can result from a number of conditions, including iron deficiency, chronic renal disease, and cancer. The European anemia medications market contains a diverse range of goods, such as erythropoietin-stimulating agents, iron supplements, and vitamin B12 supplements. These medications are used to treat various forms of anemia and can be given via injection, oral pills, or other means.

Market Dynamics

Market Growth Drivers

Anemia is a common blood disorder, and its prevalence is increasing in Europe due to factors such as aging populations, poor dietary habits, and chronic illnesses. This is expected to drive demand for anemia drugs in the region. Awareness campaigns by healthcare providers, patient organizations, and government agencies are increasing awareness about the condition and the available treatment options. This is expected to drive demand for anemia drugs as more patients seek treatment. Advances in drug development and delivery are leading to the development of innovative anemia drugs that are more effective and have fewer side effects. This is expected to drive demand for these newer, more effective therapies. Chronic kidney disease is a common cause of anemia, and its incidence is increasing in Europe. This is expected to drive demand for anemia drugs as more patients with chronic kidney disease require treatment. With this, the Governments in Europe are introducing policies and initiatives aimed at improving healthcare access and affordability, which is expected to drive demand for anemia drugs as more patients can afford treatment.

Market Restraints

The regulatory environment for anemia drugs is stringent, which can limit the entry of new players into the market and increase the cost of developing and bringing new drugs to market. Additionally, anemia drugs may have side effects that limit their use in some patients, and there may be challenges in treating patients with comorbidities such as chronic kidney disease or cancer. Other challenges include the lack of awareness about anemia among patients and healthcare providers, as well as the high cost of diagnosis and monitoring of anemia. Finally, the COVID-19 pandemic has also impacted the anemia drugs market, with disruptions to the supply chain and changes in healthcare access and utilization affecting the demand for anemia drugs.

Competitive Landscape

Key Players

  • Amgen
  • AstraZeneca
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Johnson & Johnson
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries
  • Novartis

Recent Updates

In Nov 2022, The European Commission (EC) approved Enjaymo (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD), a rare, serious, and chronic autoimmune hemolytic anemia in which the body's immune system mistakenly attacks healthy red blood cells, causing hemolysis.

The European Commission (EC) has authorized Oxbryta (voxelotor) as a treatment for hemolytic anemia in patients with Sickle Cell Disease (SCD) aged 12 years and older.

Healthcare Policies and Regulatory Landscape

The regulatory body for the Anemia drugs market varies by country. However, some of the major regulatory bodies that oversee the approval and marketing of Anemia drugs include:

  1. The European Medicines Organization is a European Union agency in charge of pharmaceutical product evaluation and supervision. It evaluates and approves new medications before they may be marketed in the EU, as well as monitors the safety and efficacy of approved drugs.
  2. The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a part of the Council of Europe and is responsible for establishing quality standards for medicines in Europe. It provides guidance on the quality control and testing of anemia drugs.

Each member state of the EU has its own National Regulatory Authorities (NRA), which is responsible for ensuring that drugs and other medicines comply with national and EU regulations. They oversee the authorization, supervision, and monitoring of anemia drugs in their respective countries.

These regulatory bodies play a crucial role in ensuring the safety and efficacy of anemia drugs and other pharmaceutical products in Europe. They help to create a transparent and predictable regulatory environment that fosters innovation and protects public health.

Reimbursement Scenario

The reimbursement scenario for anemia drugs in Europe varies across countries and depends on factors such as the type of anemia, the severity of the condition, and the specific drug used. In general, anemia drugs may be covered by national health insurance systems in Europe, although the extent of coverage may vary.

In some countries, anemia drugs are covered under a fee-for-service model, where the cost of the drug is reimbursed to the provider or the patient. In other countries, anemia drugs may be covered under a capitation model, where a fixed amount is paid to providers to cover the cost of care for patients with anemia.

Some countries may also have restrictions on the use of anemia drugs, such as requiring prior authorization or limiting coverage to specific patient populations.

In addition to national reimbursement policies, there are also European-level policies that can affect the reimbursement of anemia drugs. For example, the European Medicines Agency may recommend the use of specific anemia drugs for certain indications, which can influence reimbursement decisions by national authorities.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company Overview Product Applications and Services Recent Developments Partnerships Ecosystem Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anemia Drugs Market Segmentation

By Type (Revenue, USD Billion):

  • Iron Deficiency
  • CKD (Chronic Kidney Disease)
  • Sickle Cell
  • Aplastic
  • Erythropoietin-stimulating agents (ESAs)
  • Others

There are a variety of other drugs that may be used to treat anemia, depending on the underlying cause. These may include corticosteroids, androgens, and immunosuppressants, among others. These types of anemia drugs are used to treat different forms of anemia and may be prescribed based on the underlying cause, the severity of the anemia, and other patient factors.

By Drugs

  • Dietary Supplements
  • Medicines

By Distribution Channel (Revenue, USD Billion):

  • Hospital Pharmacy
  • Store Pharmacy
  • Online
  • Others

The distribution channel for anemia drugs in Europe is complex and multifaceted. Pharmaceutical companies must work with a variety of stakeholders, including hospital and retail pharmacies, distributors, and regulatory authorities, to ensure that their products are effectively distributed to patients who need them.

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.


Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:



Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.



Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 12 October 2023
Updated by: Vidhi Upadhyay

Related reports (by category)

Related reports (by geography)

subscribe to our newsletter